Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DMCM
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
DMCM (methyl 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate) is a beta-carboline derivative that acts as a potent, non-selective negative allosteric modulator (inverse agonist) of the benzodiazepine binding site on GABA-A receptors. Originally developed by Ferrosan, DMCM reduces GABA-mediated chloride conductance, leading to potent convulsant, proconvulsant, and anxiogenic effects in animal models. Because of these properties, it is widely used as a pharmacological research tool to induce seizures, study GABAergic neurotransmission, and screen potential anticonvulsant and anxiolytic therapeutics.
- Other names
- 4-ethyl-6,7-dimethoxy-9H-pyrido[3,4-b]indole-3-carboxylic acid methyl esterdimethoxyethyl-carbomethoxy-beta-carbolinedimethoxyethyl-carbomethoxy-β-carbolineDMCMDMCM hydrochloridemethyl 4-ethyl-6,7-dimethoxy-9H-beta-carboline-3-carboxylatemethyl 4-ethyl-6,7-dimethoxy-9H-pyrido[3,4-b]indole-3-carboxylatemethyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylatemethyl 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylatemethyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylatemethyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate
02
Targets
GABAA (Gamma-aminobutyric acid receptor)
Beyond the preview
Go deeper on DMCM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DMCM.